Kornitzer Capital Management Inc. KS Purchases New Shares in Kiniksa Pharmaceuticals International, plc $KNSA

Key Points

• Kornitzer Capital bought a new stake of 22,091 shares (~$911,000) in Kiniksa, joining other institutional buyers (e.g., Millennium Management now holds 847,124 shares) as institutions own about 53.95% of the company.
• Q1 beat and upgraded guidance: Kiniksa reported $0.27 EPS vs. $0.18 consensus and $214.3M revenue (+55% YoY), and management raised FY‑2026 revenue guidance, spurring multiple analyst price‑target increases.
• Heavy insider selling: Insiders sold 630,652 shares (~$32.49M) in the past 90 days, including CEO Sanj K. Patel’s sale of 483,654 shares (~$25.08M), executed under pre‑arranged Rule 10b5‑1 plans.

Kornitzer Capital Management Inc. KS purchased a new stake in Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA - Free Report) during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund purchased 22,091 shares of the company's stock, valued at approximately $911,000.

Several other large investors have also added to or reduced their stakes in KNSA. Amundi bought a new stake in Kiniksa Pharmaceuticals International in the first quarter valued at $348,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its position in shares of Kiniksa Pharmaceuticals International by 4.6% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 22,843 shares of the company's stock worth $507,000 after buying an additional 1,002 shares during the period. Millennium Management LLC grew its position in shares of Kiniksa Pharmaceuticals International by 8.7% in the 1st quarter. Millennium Management LLC now owns 847,124 shares of the company's stock worth $18,815,000 after buying an additional 67,452 shares during the period. Creative Planning purchased a new stake in shares of Kiniksa Pharmaceuticals International in the 2nd quarter worth about $358,000. Finally, Quantbot Technologies LP purchased a new stake in shares of Kiniksa Pharmaceuticals International in the 2nd quarter worth about $43,000. Institutional investors own 53.95% of the company's stock.

Insiders Place Their Bets

In other Kiniksa Pharmaceuticals International news, CAO Michael R. Megna sold 6,625 shares of the business's stock in a transaction dated Thursday, April 9th. The stock was sold at an average price of $46.69, for a total value of $309,321.25. Following the completion of the transaction, the chief accounting officer owned 27,418 shares of the company's stock, valued at approximately $1,280,146.42. The trade was a 19.46% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Sanj K. Patel sold 483,654 shares of the business's stock in a transaction dated Tuesday, April 28th. The stock was sold at an average price of $51.86, for a total value of $25,082,296.44. Following the completion of the transaction, the chief executive officer directly owned 431,904 shares of the company's stock, valued at approximately $22,398,541.44. This trade represents a 52.83% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 630,652 shares of company stock worth $32,490,737 in the last 90 days. Corporate insiders own 53.48% of the company's stock.

More Kiniksa Pharmaceuticals International News

Here are the key news stories impacting Kiniksa Pharmaceuticals International this week:

• Positive Sentiment: Q1 beat and upgraded guidance — Kiniksa reported $0.27 EPS vs. $0.18 consensus and revenue of $214.3M (≈+55% YoY); management raised FY‑2026 revenue guidance, improving near‑term revenue visibility. Q1 Results & Guidance
• Positive Sentiment: Analyst upgrades/target raises — multiple brokers lifted targets (examples: Jefferies to $71, Canaccord to $64, Citi to $60, Wedbush to $59), which supports buying interest and helped push the stock higher. Analyst Target Raises
• Positive Sentiment: Product and pipeline momentum — ARCALYST reported strong Q1 net product revenue and management raised expectations; KPL‑387 Phase‑2 readout (recurrent pericarditis) is expected 2H‑2026 with a planned Phase‑3 start by year‑end, offering future catalysts. Product & Pipeline
• Neutral Sentiment: Earnings materials available — Q1 slide deck and call transcript posted for investors who want to verify channel dynamics, margin assumptions and guidance drivers. Earnings Presentation
• Negative Sentiment: Large insider selling — CEO Sanj K. Patel executed significant sales (including 483,654 shares on Apr. 28 and additional tranches Apr. 29–30) under a pre‑arranged 10b5‑1 plan; director Barry Quart also sold ~13k shares. Heavy insider selling can create short‑term negative sentiment despite being pre‑planned. CEO SEC Filing
• Negative Sentiment: Director sale detail — Director Barry D. Quart sold 13,099 shares (~$50.10 avg) under a 10b5‑1 plan, reducing his stake materially; additional SEC filing here. Director SEC Filing

Kiniksa Pharmaceuticals International Price Performance

KNSA stock opened at $55.27 on Monday. Kiniksa Pharmaceuticals International, plc has a 1-year low of $24.85 and a 1-year high of $55.28. The business has a fifty day moving average price of $46.40 and a 200-day moving average price of $43.20. The stock has a market capitalization of $4.23 billion, a P/E ratio of 61.41 and a beta of 0.17.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA - Get Free Report) last issued its earnings results on Tuesday, April 28th. The company reported $0.27 earnings per share for the quarter, topping analysts' consensus estimates of $0.18 by $0.09. Kiniksa Pharmaceuticals International had a return on equity of 13.26% and a net margin of 9.69%.The business had revenue of $214.27 million during the quarter, compared to analyst estimates of $206.11 million. During the same quarter in the previous year, the firm earned $0.11 EPS. Kiniksa Pharmaceuticals International's revenue was up 55.5% on a year-over-year basis. As a group, analysts anticipate that Kiniksa Pharmaceuticals International, plc will post 1.22 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of analysts have recently weighed in on the stock. Wall Street Zen raised shares of Kiniksa Pharmaceuticals International from a "hold" rating to a "strong-buy" rating in a research report on Monday. Jefferies Financial Group upped their price target on shares of Kiniksa Pharmaceuticals International from $58.00 to $71.00 and gave the stock a "buy" rating in a research note on Tuesday, April 28th. Wells Fargo & Company upped their price target on shares of Kiniksa Pharmaceuticals International from $53.00 to $57.00 and gave the stock an "overweight" rating in a research note on Wednesday, April 29th. Weiss Ratings reiterated a "hold (c)" rating on shares of Kiniksa Pharmaceuticals International in a research note on Tuesday, April 21st. Finally, Canaccord Genuity Group upped their price target on shares of Kiniksa Pharmaceuticals International from $62.00 to $64.00 and gave the stock a "buy" rating in a research note on Wednesday, April 29th. Seven research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company's stock. According to data from MarketBeat.com, Kiniksa Pharmaceuticals International currently has an average rating of "Moderate Buy" and an average target price of $60.86.

Kiniksa Pharmaceuticals International Profile

Kiniksa Pharmaceuticals International, Inc is a biopharmaceutical company focused on discovering, acquiring and developing therapeutics for patients suffering from lifethreatening and debilitating immune-mediated diseases. Founded in 2013 and headquartered in Lexington, Massachusetts, Kiniksa applies a patient-centric approach to build a diversified portfolio of marketed medicines and clinical-stage candidates targeting inflammation and immunology. The company's core mission is to address complex conditions with significant unmet medical needs by advancing both novel and differentiated therapies.

The company's lead marketed product is Ilaris (canakinumab), an interleukin-1β blocker licensed for the treatment of cryopyrin-associated periodic syndromes, systemic juvenile idiopathic arthritis, adult-onset Still's disease and Schnitzler syndrome.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.